Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.

Viking Therapeutics jumped by 9.74 percent on Tuesday to close at $30.19 apiece as investors repositioned portfolios ahead of ...

Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and ...

NMRA-861 has demonstrated a potentially best-in-class pharmacological profile and robust activity in preclinical efficacy models. NMRA-861 was safe and well-tolerated in pre-clinical toxicology ...

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

A systematic review of almost 50 randomized clinical trials brings some clarity to concerns about antidepressant withdrawal ...

GMP manufacturing completed, paediatric waiver granted, positive outcome from FDA and EMA interactions; advancing mitazalimab toward Phase 3 readinessBiomarker data from OPTIMIZE-1 presented at ASCO, ...

People like Big Bear Lake resident Mike Etchamendy count on clinical trials to survive. “You cut funding there, you’re going ...

As patients increasingly turn to cannabis for chronic pain, clinicians grapple with mixed evidence and a lack of high-quality ...

Women health care providers assigned to transcendental meditation vs. usual treatment had better burnout and anxiety scores at 3 months, according to data presented at the American Thoracic Society ...

ARO-C3 is an investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potential therapy for various complement-mediated diseases.

Revolution Medicines' proprietary data will train a bespoke version of NeuralPLexer, an AI model for protein-ligand ...